| |
Newsroom /
Medical
/
Medical
/
Urinary Incontinence (UI) - Drug Pipeline Analysis and Market Forecasts to 2016
Urinary Incontinence (UI) - Drug Pipeline Analysis and Market Forecasts to 2016
The UI Therapeutics Market is Forecast to Show Modest Growth until 2016
Hyderabad,
AP,
India
(prbd.net)
31/03/2010
"Urinary Incontinence (UI) - Drug Pipeline Analysis and Market Forecasts to 2016"
The global UI therapeutics market was worth approximately $1.8 billion in 2009. In 2001 the market was valued at $1.3 billion and it grew at an approximate CAGR of 4.2% from 2001 to 2009. The global UI therapeutics market is expected to reach $2.7 billion by 2016 after growing at a CAGR of 6.3%. The primary factors contributing to the increase in growth over the forecast period will be the increase in disease incidence and the entry of novel efficacious drugs. Presently the therapeutic regimen for UI is dominated by a range of muscarinic receptor antagonists (anticholinergic drugs) which include Detrol LA, Dirtopan, Enablex, Toviaz, Sanctura XR and VESIcare. This market is a significantly genericized market with many brands across the seven geographies. Tablet prices range between $1.5 and $5 depending on the brands. The average annual cost of therapy for UI therapeutics ranges between $550 and $1,750.
The market has limited scope for growth due to the presence of generic products and the lack of innovation with respect to better efficacy and safety drug profiles. The UI developmental pipeline is weak with only 26 molecules in various phases of clinical development. There are 14 first-in-class molecules over all phases of development. Overall there are six molecules whose mechanisms of action are not known or have not been disclosed by the parent company. Phase III contains five first-in-class molecules. These include platelet acetylcholine blockers, Beta-3 adrenoceptor agonists, calcium influx inhibitors and intracellular calcium modulators and combinational therapies employing molecules which are Beta-3 adrenoceptor agonists, muscarinic receptor antagonists. Phase II contains seven first-in-class molecules.
The UI therapeutics market has moderate to low unmet needs in terms of both efficacy and safety. The low unmet needs imply that the market is well served by the current product options, and has low scope available to new entrants that could capture value from the underserved segments. The efficacy of the present therapeutics ranges from moderate to strong with a couple of therapeutic classes having significantly strong efficacy profiles. The therapeutic interventions for UI are primarily limited only to oral formulations in tablet form. Since the market is genericized, there are many available brands and the drugs are cheap.
Safety is a moderate concern for this market. The occurrence of dry mouth and constipation is prevalent among the patient population and safer drugs are needed. Apart from these complications, dizziness, nausea and flu-like symptoms are also common side effects for the present therapeutics drugs. The need for safer drugs especially with respect to the target population which include patients between the ages of 50 and 80 years is the primary unmet need for the UI therapeutics market.
GlobalData, the industry analysis specialist’s new report, “Urinary Incontinence (UI) - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global UI market. The report identifies the key trends shaping and driving the dynamism in the global UI market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global UI market.
http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|